Drug Profile

BHV 2100

Alternative Names: BHV-2100

Latest Information Update: 03 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Centre for Drug Design and Discovery; Katholieke Universiteit Leuven
Developer Biohaven Therapeutics; Katholieke Universiteit Leuven
Class Analgesics; Antimigraines; Small molecules
Mechanism of Action TRPM3 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Migraine
Phase I Pain

Most Recent Events

05 Apr 2025 Pharmacokinetic and adverse events data from a phase I trial in Migraine presented at the 77th Annual Meeting of the American Academy of Neurology 2025 (AAN-2025)
28 Mar 2025 Biohaven Therapeutics completes a phase II trial in Migraine in USA (PO) (NCT06603623)
12 Nov 2024 Phase-I clinical trials in Pain (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com